微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 46.42% | -12.83% | -1.85% | 84/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 47.29% | -12.47% | -3.31% | 80/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 48.91% | -9.1% | -8.51% | 71/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 53.46% | -8.44% | 0.4% | 73/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 53.25% | -9.72% | -1.45% | 71/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 54.03% | -8.34% | 0.41% | 71/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 53.81% | -6.9% | -7.84% | 65/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 58.39% | 2.57% | -1.01% | 60/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 58.98% | -23.17% | 0.07% | 58/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 58.94% | -21.55% | 1.99% | 58/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 57.8% | -23.62% | 1.53% | 60/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 56.92% | -22.68% | -25.86% | 68/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 76.78% | 2.37% | 2.19% | 29/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 75.13% | -0.76% | -0.71% | 32/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 75.67% | 0.71% | 2.79% | 30/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 73.62% | -0.57% | -1.84% | 36/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 75% | 2.78% | -0.94% | 27/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 75.71% | 6.49% | 0.76% | 28/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 75.14% | 10.62% | 1.48% | 23/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 74.04% | 0.94% | 1.47% | 31/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 72.97% | -0.32% | 2.64% | 27/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 71.09% | -4.29% | 4.67% | 30/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 67.92% | -7.06% | -7.4% | 31/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 73.35% | -1.6% | 0.2% | 29/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 73.2% | -0.91% | -1.46% | 22/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 74.28% | 1.3% | 1.65% | 23/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 73.08% | 0.64% | -1.97% | 19/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 74.55% | 5.63% | 0.9% | 27/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 73.88% | 13.17% | 0.75% | 17/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 73.33% | 22.25% | 0.98% | 17/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 72.62% | 24.28% | 2.9% | 17/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 70.57% | 20.33% | 8.11% | 26/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 65.28% | 10.65% | 8.83% | 24/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 59.99% | 2.4% | 2.66% | 30/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 58.43% | -3.42% | -0.37% | 25/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 58.65% | -7.19% | -0.59% | 33/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 59% | -7.39% | 0.72% | 22/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 58.58% | -8.12% | -3.18% | 26/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 60.5% | -4.17% | -4.26% | 20/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 63.2% | 0.37% | -0.8% | 22/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 63.71% | 2.02% | -0.08% | 16/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 63.76% | 3.54% | 0.99% | 17/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 63.14% | 0.03% | 0.28% | 15/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |